Hims takes a blow from Lilly’s vial news

Good morning. As a treat for Labor Day weekend, we’re running a deal for STAT+ subscriptions. If you use the code LABORDAY at checkout, you can get 25% off your first year. Learn more here.

Now onto the biotech news of the day.

The need-to-know this morning

• Neurocrine Biosciences said the lowest dose of an experimental pill for schizophrenia reduced psychosis reported by patients in a mid-stage study, but higher doses of the drug also tested were ineffective.

• Bayer and NextRNA Therapeutics announced a collaboration to develop RNA-based, small molecule drugs for cancer.

Pfizer partners with Flagship company on heart and renal drugs

Flagship Pioneering said today that one of its biotechs, Quotient Therapeutics, will partner with Pfizer to identify new targets for cardiovascular and renal drugs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In